Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 973 across all filing types
Latest filing 2018-04-13 AGM Information
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon ASA - Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'Notice of Annual General Meeting' and details the date, time, and location for the meeting. It also mentions that the registration form and notice are being sent out. This directly relates to the Annual General Meeting (AGM) process. Although it mentions the annual report is published separately, the primary content is the notice for the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length is short (1103 chars), but the content is the notice, not just an announcement that a notice exists, making AGM-R more specific than RPA or RNS.
2018-04-13 English
Biotec Pharmacon - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled "Mandatory notification of trade" and explicitly details a purchase of shares by a company executive (Rolf E. Engstad, CSO). This transaction involves an insider (director/executive) trading the company's stock. This directly corresponds to the definition of Director's Dealing (DIRS). The short length (611 chars) and the nature of the content confirm it is a specific regulatory disclosure rather than a general announcement or a full report.
2018-03-19 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists key dates for the financial year 2018, including dates for Quarterly Reports, Half-yearly Reports, and specifically mentions the 'Annual General Meeting' (AGM) date change. Since the document is very short (600 chars) and primarily serves as an announcement of future events and dates, it is not the AGM presentation itself (AGM-R) or a full financial report (10-K, IR). It is an announcement related to corporate events and scheduling. Given the explicit mention of the AGM date and the general nature of announcing corporate schedule items, AGM-R (AGM Information) is the most relevant category, as the AGM date is a central piece of information provided, even if it's part of a broader calendar. However, since it is a calendar announcement, it could also be RNS. Given the high specificity of AGM-R, and the AGM being a highlighted event, I will lean towards AGM-R, but acknowledge the calendar aspect. Re-evaluating based on definitions: AGM-R is for 'Presentations and materials shared during the AGM'. This is a calendar announcement. Since there is no specific 'Calendar Announcement' code, and it is a regulatory disclosure ('published pursuant to the requirements set out in the Continuing obligations'), RNS (Regulatory Filings) is the safest fallback for a general schedule announcement that doesn't fit the specific report types. However, the AGM date is prominent. Let's check AGM-R again. If the document was the material *for* the AGM, it would be AGM-R. Since it's just the *date*, RNS is more appropriate as a general regulatory disclosure about scheduling. I will classify it as RNS as it is a general regulatory update/calendar announcement.
2018-03-15 English
Strong Woulgan results from 300 patient study
Regulatory Filings Classification · 90% confidence The document is explicitly labeled as a "Press release" and details the positive results of a 300-patient study regarding their product, Woulgan® Gel. It announces new data that the company intends to use in marketing efforts. This type of announcement, focusing on new scientific or operational results without being a full financial report (like 10-K or IR) or a formal earnings release (ER) which typically focuses on revenue/profit metrics, fits best under a general announcement category. Since it is not a formal regulatory filing (like a 10-K or DEF 14A) and is not a transcript, presentation, or specific financial notice, it is classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially an Earnings Release (ER) if the study results are considered the primary 'result' for the period, but given the focus on product efficacy rather than period financials, RNS is a safer fit, or potentially a general Investor Relations document. However, looking closely at the definitions, it is a release of new information intended for the market. It is not a Call Transcript (CT), Investor Presentation (IP), or Earnings Release (ER) which usually contains P&L figures. It is a general announcement of positive findings. Given the options, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category for a press release detailing study results that doesn't fit a more specific financial or governance category.
2018-03-01 English
Strong Woulgan results from 300 patient study
Regulatory Filings Classification · 95% confidence The document is a press release dated March 1, 2018, announcing positive results from a 300-patient study regarding the effectiveness of Woulgan® Gel for treating stalled wounds. It details the study design, statistical outcomes (p < 0.01), and quotes the CEO about using this data for marketing. This content is an announcement of new scientific/clinical data, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is a specific announcement about clinical findings intended for investors and the public, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, although it is more specific than a typical RNS. Given the options, it is a general corporate announcement about product performance/data, which often falls under RNS if no other category fits perfectly. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Supplement (XLSX). It is an announcement, not a report itself, so RPA is less likely as it's not announcing the publication of a formal report, but rather the results themselves.
2018-03-01 English
Styreleder fratrer ved 2018 generalforsamling
Board/Management Information Classification · 98% confidence The document text, written in Norwegian, announces that the Chairman of the Board (Styreleder) Erik Thorsen will step down at the 2018 General Meeting (generalforsamling). This directly relates to changes in the company's board of directors or senior management. Based on the definitions, this aligns perfectly with the Board/Management Information category (MANG). The document length is very short (608 chars), but the content is a direct announcement of a management change, not an announcement about the publication of a report.
2018-02-01 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.